{"protocolSection": {"identificationModule": {"nctId": "NCT03692676", "orgStudyIdInfo": {"id": "0205-0537"}, "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "Characteristics of Pts Initiating Spiriva Respimat in Asthma", "officialTitle": "Characteristics of Patients Initiating Spiriva Respimat in Asthma in the UK: a Cross-sectional Study Based on the Clinical Practice Research Datalink"}, "statusModule": {"statusVerifiedDate": "2021-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2019-03-05", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-10-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-10-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-09-25", "studyFirstSubmitQcDate": "2018-09-26", "studyFirstPostDateStruct": {"date": "2018-10-02", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2020-10-08", "resultsFirstSubmitQcDate": "2020-12-18", "resultsFirstPostDateStruct": {"date": "2020-12-21", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-11-12", "lastUpdatePostDateStruct": {"date": "2021-11-15", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": false, "isFdaRegulatedDevice": true, "isUsExport": false}, "descriptionModule": {"briefSummary": "This study is a cross-sectional, non-interventional study based on existing data (NISed).", "detailedDescription": "The UK CPRD data will be used to assess the characteristics of asthma patients who were prescribed ICS/LABA FDC before the index date and who initiated Spiriva Respimat, or received a higher dose of ICS/LABA FDC, or initiated LTRA, or switched to a new ICS/LABA FDC in the UK during the study period (September 2014-December 2017) enabling to assess potential channeling of prescribing to different patient populations."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "OBSERVATIONAL", "patientRegistry": false, "designInfo": {"observationalModel": "COHORT", "timePerspective": "CROSS_SECTIONAL"}, "enrollmentInfo": {"count": 116133, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Subjects with Asthma", "description": "Asthmatic patients prescribed Inhaled corticosteroids/Long-acting beta agonists (ICS/LABA FDC) before index date, initiated with Spiriva Respimat, or received a higher dose of ICS/LABA FDC, initiated LTRA , or switched to a new ICS/LABA FDC fom the previous ICS/LABA FDC", "interventionNames": ["Device: Spiriva Respimat"]}], "interventions": [{"type": "DEVICE", "name": "Spiriva Respimat", "description": "soft-mist inhaler", "armGroupLabels": ["Subjects with Asthma"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With Cardiac Arrhythmias", "description": "The number of participants who had Cardiac arrhythmias on the index date or in the year prior to the index date.", "timeFrame": "On the index date or in the year prior to the index date"}], "secondaryOutcomes": [{"measure": "Number of Participants With Cardiac Failure", "description": "The number of participants who had Cardiac failure on the index date or in the year prior to the index date.", "timeFrame": "On the index date or in the year prior to the index date"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Aged 18 years and above at the index date\n* At least 12 months of continuous registration prior to the index date in a practice contributing up to standard (UTS) data to the Clinical Practice Research Database (CPRD)\n* Had a diagnosis of asthma before the index date\n* Being treated with Inhaled corticosteroids/Long-acting beta agonists (ICS LABA FDC) before the index date (at least one prescription within 3 months before the index date)\n* Patients who were new users of Spiriva Respimat, or LTRA, or patients who were prescribed a higher dose of ICS/LABA FDC, or patients who switched to a new ICS/LABA FDC from the previous ICS/LABA FDC\n\nExclusion Criteria:\n\n* Patients who were prescribed other Long-acting muscarinic antagonists (LAMA) any time before or on the index date\n* In the primary analysis, patients who were diagnosed with COPD before or on the index date will be excluded from the study. In a sensitivity analysis, patients who had both asthma and COPD diagnoses will be included in the study", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "Asthmatic patients who were prescribed ICS/LABA FDC before the index date and who initiated Spiriva Respimat, or received a higher dose of ICS/LABA FDC, or initiated LTRA, or switched to a new ICS/LABA FDC from the previous ICS/LABA FDC in the UK during the study period (September, 2014-December 31, 2017)", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"locations": [{"facility": "Boehringer Ingelheim", "city": "Ingelheim", "country": "Germany"}]}, "ipdSharingStatementModule": {"ipdSharing": "NO", "description": "Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:\n\n1. studies in products where Boehringer Ingelheim is not the license holder;\n2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;\n3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).\n\nFor more details refer to: https://www.mystudywindow.com/msw/datasharing"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "All subjects were screened for eligibility to participate in trial. Subjects meeting the exclusion criteria were excluded.", "recruitmentDetails": "This study is a cross-sectional assessment of asthma patients who initiated Spiriva Respimat, who initiated leukotriene receptor antagonist (LTRA), who received a higher dose of ICS/LABA FDC, or who switched to a new ICS/LABA FDC in asthma in the UK during the study period (September, 2014-December 31, 2017). (Non-interventional study based on existing data).", "groups": [{"id": "FG000", "title": "Spiriva Respimat", "description": "The first Spiriva Respimat prescription record during study period qualifies for cohort entry and its event date will be set as index date.\n\nPatients will be excluded if they fulfill any of the following exclusion criteria:\n\n* prior Spiriva Respimat use before index date\n* no Inhaled corticosteroids (ICS)/ Long-acting beta agonists (LABA) Fixed Dose Combination (FDC) Prescription Record (Rx) within 3 months before index date\n* no prior asthma Diagnosis Record (Dx) before index date\n* age on index date less than 18 years\n* on index date less than 365 days prior Up-to-standard (UTS) registration\n* prior Chronic Obstructive Pulmonary Disease (COPD) Dx before index date (including index date)\n* any prior Long-acting muscarinic antagonists (LAMA) use (including index date)"}, {"id": "FG001", "title": "Leukotriene Receptor Antagonist (LTRA)", "description": "The first LTRA prescription record during study period qualifies for cohort entry and its event date will be set as index date.\n\nPatients will be excluded if they fulfill any of the following exclusion criteria:\n\n* prior LTRA use before index date\n* no ICS/LABA FDC Rx within 3 months before index date\n* no prior asthma Dx before index date age on index date less than 18 years\n* on index date less than 365 days prior UTS registration\n* prior COPD Dx before index date (including index date)\n* any prior LAMA use before index date (including index date)"}, {"id": "FG002", "title": "ICS/LABA Fixed Dose Combination (Switchers)", "description": "The first ICS/LABA FDC prescription record during study period with different ICS and/or LABA drug substance component as compared to the preceding FDC prescription qualifies for cohort entry and its event date will be set as index date. Same ICS/LABA FDC, but different device (e.g. switch from DPI to pMDI) will trigger cohort entry to this cohort as well.\n\nPatients will be excluded if they fulfil any of the following exclusion criteria:\n\n* prior use of the same ICS/LABA FDC (evaluated on drug substance and device level) before index date\n* preceding ICS/LABA FDC Rx not within 3 months before index date\n* no prior asthma Dx before index date\n* age on index date less than 18 years\n* on index date less than 365 days prior UTS registration\n* prior COPD Dx before index date (including index date)\n* any prior LAMA use before index date (including index date)"}, {"id": "FG003", "title": "ICS Dose Increase of ICS/LABA Fixed Dose Combination User", "description": "The first ICS/LABA FDC prescription record during study period which represent a dose increase of ICS daily dose as compared to the preceding FDC prescription qualifies for cohort entry and its event date will be set as index date.\n\nPatients will be excluded if they fulfill any of the following exclusion criteria:\n\n* preceding ICS/LABA FDC Rx within 3 months before index date\n* no prior asthma Dx before index date\n* age on index date less than 18 years\n* on index date less than 365 days prior UTS registration\n* prior COPD Dx before index date (incl. index date)\n* any prior LAMA use before index date (incl. index date)"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "10365"}, {"groupId": "FG001", "numSubjects": "51142"}, {"groupId": "FG002", "numSubjects": "49479"}, {"groupId": "FG003", "numSubjects": "5147"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "940"}, {"groupId": "FG001", "numSubjects": "3704"}, {"groupId": "FG002", "numSubjects": "11135"}, {"groupId": "FG003", "numSubjects": "1561"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9425"}, {"groupId": "FG001", "numSubjects": "47438"}, {"groupId": "FG002", "numSubjects": "38344"}, {"groupId": "FG003", "numSubjects": "3586"}]}], "dropWithdraws": [{"type": "exclude patients with prior use", "reasons": [{"groupId": "FG000", "numSubjects": "4424"}, {"groupId": "FG001", "numSubjects": "24726"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "exclude patients without concurrent ICS/LABA FDC use", "reasons": [{"groupId": "FG000", "numSubjects": "2480"}, {"groupId": "FG001", "numSubjects": "19037"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "exclude patients without prior recorded asthma diagnosis", "reasons": [{"groupId": "FG000", "numSubjects": "881"}, {"groupId": "FG001", "numSubjects": "563"}, {"groupId": "FG002", "numSubjects": "6281"}, {"groupId": "FG003", "numSubjects": "558"}]}, {"type": "exclude patients less than 18 years of age on index date", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "613"}, {"groupId": "FG002", "numSubjects": "836"}, {"groupId": "FG003", "numSubjects": "193"}]}, {"type": "exclude patients with less than 1 year prior continous UTS enrollment", "reasons": [{"groupId": "FG000", "numSubjects": "149"}, {"groupId": "FG001", "numSubjects": "717"}, {"groupId": "FG002", "numSubjects": "1723"}, {"groupId": "FG003", "numSubjects": "273"}]}, {"type": "exclude patients with prior LAMA use (any time prior to index date)", "reasons": [{"groupId": "FG000", "numSubjects": "1208"}, {"groupId": "FG001", "numSubjects": "759"}, {"groupId": "FG002", "numSubjects": "7419"}, {"groupId": "FG003", "numSubjects": "684"}]}, {"type": "exclude patients with prior recorded COPD diagnosis", "reasons": [{"groupId": "FG000", "numSubjects": "275"}, {"groupId": "FG001", "numSubjects": "218"}, {"groupId": "FG002", "numSubjects": "1515"}, {"groupId": "FG003", "numSubjects": "173"}]}, {"type": "exclude patients with multiple FDC prescriptions on index date", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1147"}, {"groupId": "FG003", "numSubjects": "4"}]}, {"type": "exclude patients with prior use of same substances and device", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "3700"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "exclude patients without ICS/LABA FDC prescription within 3 months prior to index date", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "14965"}, {"groupId": "FG003", "numSubjects": "1198"}]}, {"type": "exclude patients with different substance(s)/device at preceding prescription", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "223"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "805"}, {"groupId": "FG002", "numSubjects": "758"}, {"groupId": "FG003", "numSubjects": "277"}]}, {"type": "exclude patients with multiple substance(s)/device at preceding prescription", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Asthma patients who initiated Spiriva Respimat, who initiated leukotriene receptor antagonist (LTRA), who received a higher dose of ICS/LABA FDC, or who switched to a new ICS/LABA FDC in asthma, and who did not violate any of the exclusion criteria, in the United Kingdom during the study period (Sep 2014 - Dec 2017).", "groups": [{"id": "BG000", "title": "Spiriva Respimat", "description": "The first Spiriva Respimat prescription record during study period qualifies for cohort entry and its event date will be set as index date.\n\nPatients will be excluded if they fulfill any of the following exclusion criteria:\n\n* prior Spiriva Respimat use before index date\n* no Inhaled corticosteroids (ICS)/ Long-acting beta agonists (LABA) Fixed Dose Combination (FDC) Prescription Record (Rx) within 3 months before index date\n* no prior asthma Diagnosis Record (Dx) before index date\n* age on index date less than 18 years\n* on index date less than 365 days prior Up-to-standard (UTS) registration\n* prior Chronic Obstructive Pulmonary Disease (COPD) Dx before index date (including index date)\n* any prior Long-acting muscarinic antagonists (LAMA) use (including index date)"}, {"id": "BG001", "title": "Leukotriene Receptor Antagonist (LTRA)", "description": "The first LTRA prescription record during study period qualifies for cohort entry and its event date will be set as index date.\n\nPatients will be excluded if they fulfill any of the following exclusion criteria:\n\n* prior LTRA use before index date\n* no ICS/LABA FDC Rx within 3 months before index date\n* no prior asthma Dx before index date age on index date less than 18 years\n* on index date less than 365 days prior UTS registration\n* prior COPD Dx before index date (including index date)\n* any prior LAMA use before index date (including index date)"}, {"id": "BG002", "title": "ICS/LABA Fixed Dose Combination (Switchers)", "description": "The first ICS/LABA FDC prescription record during study period with different ICS and/or LABA drug substance component as compared to the preceding FDC prescription qualifies for cohort entry and its event date will be set as index date. Same ICS/LABA FDC, but different device (e.g. switch from DPI to pMDI) will trigger cohort entry to this cohort as well.\n\nPatients will be excluded if they fulfil any of the following exclusion criteria:\n\n* prior use of the same ICS/LABA FDC (evaluated on drug substance and device level) before index date\n* preceding ICS/LABA FDC Rx not within 3 months before index date\n* no prior asthma Dx before index date\n* age on index date less than 18 years\n* on index date less than 365 days prior UTS registration\n* prior COPD Dx before index date (including index date)\n* any prior LAMA use before index date (including index date)"}, {"id": "BG003", "title": "ICS Dose Increase of ICS/LABA Fixed Dose Combination User", "description": "The first ICS/LABA FDC prescription record during study period which represent a dose increase of ICS daily dose as compared to the preceding FDC prescription qualifies for cohort entry and its event date will be set as index date.\n\nPatients will be excluded if they fulfill any of the following exclusion criteria:\n\n* preceding ICS/LABA FDC Rx within 3 months before index date\n* no prior asthma Dx before index date\n* age on index date less than 18 years\n* on index date less than 365 days prior UTS registration\n* prior COPD Dx before index date (incl. index date)\n* any prior LAMA use before index date (incl. index date)"}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "940"}, {"groupId": "BG001", "value": "3704"}, {"groupId": "BG002", "value": "11135"}, {"groupId": "BG003", "value": "1561"}, {"groupId": "BG004", "value": "17340"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Year", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "54.22", "spread": "15.741"}, {"groupId": "BG001", "value": "49.12", "spread": "16.299"}, {"groupId": "BG002", "value": "53.31", "spread": "16.961"}, {"groupId": "BG003", "value": "51.91", "spread": "17.189"}, {"groupId": "BG004", "value": "52.34", "spread": "16.77"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "653"}, {"groupId": "BG001", "value": "2479"}, {"groupId": "BG002", "value": "7121"}, {"groupId": "BG003", "value": "979"}, {"groupId": "BG004", "value": "11232"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "287"}, {"groupId": "BG001", "value": "1225"}, {"groupId": "BG002", "value": "4014"}, {"groupId": "BG003", "value": "582"}, {"groupId": "BG004", "value": "6108"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "25"}, {"groupId": "BG001", "value": "90"}, {"groupId": "BG002", "value": "210"}, {"groupId": "BG003", "value": "42"}, {"groupId": "BG004", "value": "367"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "9"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "71"}, {"groupId": "BG003", "value": "9"}, {"groupId": "BG004", "value": "119"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "527"}, {"groupId": "BG001", "value": "1996"}, {"groupId": "BG002", "value": "5896"}, {"groupId": "BG003", "value": "776"}, {"groupId": "BG004", "value": "9195"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "99"}, {"groupId": "BG003", "value": "14"}, {"groupId": "BG004", "value": "166"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "366"}, {"groupId": "BG001", "value": "1548"}, {"groupId": "BG002", "value": "4859"}, {"groupId": "BG003", "value": "720"}, {"groupId": "BG004", "value": "7493"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With Cardiac Arrhythmias", "description": "The number of participants who had Cardiac arrhythmias on the index date or in the year prior to the index date.", "populationDescription": "Asthma patients who initiated Spiriva Respimat, who initiated leukotriene receptor antagonist (LTRA), who received a higher dose of ICS/LABA FDC, or who switched to a new ICS/LABA FDC in asthma, and who did not violate any of the exclusion criteria, in the United Kingdom during the studied period (Sep 2014 - Dec 2017).", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "On the index date or in the year prior to the index date", "groups": [{"id": "OG000", "title": "Spiriva Respimat", "description": "The first Spiriva Respimat prescription record during study period qualifies for cohort entry and its event date will be set as index date.\n\nPatients will be excluded if they fulfill any of the following exclusion criteria:\n\n* prior Spiriva Respimat use before index date\n* no Inhaled corticosteroids (ICS)/ Long-acting beta agonists (LABA) Fixed Dose Combination (FDC) Prescription Record (Rx) within 3 months before index date\n* no prior asthma Diagnosis Record (Dx) before index date\n* age on index date less than 18 years\n* on index date less than 365 days prior Up-to-standard (UTS) registration\n* prior Chronic Obstructive Pulmonary Disease (COPD) Dx before index date (including index date)\n* any prior Long-acting muscarinic antagonists (LAMA) use (including index date)"}, {"id": "OG001", "title": "Leukotriene Receptor Antagonist (LTRA)", "description": "The first LTRA prescription record during study period qualifies for cohort entry and its event date will be set as index date.\n\nPatients will be excluded if they fulfill any of the following exclusion criteria:\n\n* prior LTRA use before index date\n* no ICS/LABA FDC Rx within 3 months before index date\n* no prior asthma Dx before index date age on index date less than 18 years\n* on index date less than 365 days prior UTS registration\n* prior COPD Dx before index date (including index date)\n* any prior LAMA use before index date (including index date)"}, {"id": "OG002", "title": "ICS/LABA Fixed Dose Combination (Switchers)", "description": "The first ICS/LABA FDC prescription record during study period with different ICS and/or LABA drug substance component as compared to the preceding FDC prescription qualifies for cohort entry and its event date will be set as index date. Same ICS/LABA FDC, but different device (e.g. switch from DPI to pMDI) will trigger cohort entry to this cohort as well.\n\nPatients will be excluded if they fulfil any of the following exclusion criteria:\n\n* prior use of the same ICS/LABA FDC (evaluated on drug substance and device level) before index date\n* preceding ICS/LABA FDC Rx not within 3 months before index date\n* no prior asthma Dx before index date\n* age on index date less than 18 years\n* on index date less than 365 days prior UTS registration\n* prior COPD Dx before index date (including index date)\n* any prior LAMA use before index date (including index date)"}, {"id": "OG003", "title": "ICS Dose Increase of ICS/LABA Fixed Dose Combination User", "description": "The first ICS/LABA FDC prescription record during study period which represent a dose increase of ICS daily dose as compared to the preceding FDC prescription qualifies for cohort entry and its event date will be set as index date.\n\nPatients will be excluded if they fulfill any of the following exclusion criteria:\n\n* preceding ICS/LABA FDC Rx within 3 months before index date\n* no prior asthma Dx before index date\n* age on index date less than 18 years\n* on index date less than 365 days prior UTS registration\n* prior COPD Dx before index date (incl. index date)\n* any prior LAMA use before index date (incl. index date)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "940"}, {"groupId": "OG001", "value": "3704"}, {"groupId": "OG002", "value": "11135"}, {"groupId": "OG003", "value": "1561"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "102"}, {"groupId": "OG003", "value": "16"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Cardiac Failure", "description": "The number of participants who had Cardiac failure on the index date or in the year prior to the index date.", "populationDescription": "Asthma patients who initiated Spiriva Respimat, who initiated leukotriene receptor antagonist (LTRA), who received a higher dose of ICS/LABA FDC, or who switched to a new ICS/LABA FDC in asthma, and who did not violate any of the exclusion criteria, in the United Kingdom during the studied period (Sep 2014 - Dec 2017).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Patients with cardiac failures", "timeFrame": "On the index date or in the year prior to the index date", "groups": [{"id": "OG000", "title": "Spiriva Respimat", "description": "The first Spiriva Respimat prescription record during study period qualifies for cohort entry and its event date will be set as index date.\n\nPatients will be excluded if they fulfill any of the following exclusion criteria:\n\n* prior Spiriva Respimat use before index date\n* no Inhaled corticosteroids (ICS)/ Long-acting beta agonists (LABA) Fixed Dose Combination (FDC) Prescription Record (Rx) within 3 months before index date\n* no prior asthma Diagnosis Record (Dx) before index date\n* age on index date less than 18 years\n* on index date less than 365 days prior Up-to-standard (UTS) registration\n* prior Chronic Obstructive Pulmonary Disease (COPD) Dx before index date (including index date)\n* any prior Long-acting muscarinic antagonists (LAMA) use (including index date)"}, {"id": "OG001", "title": "Leukotriene Receptor Antagonist (LTRA)", "description": "The first LTRA prescription record during study period qualifies for cohort entry and its event date will be set as index date.\n\nPatients will be excluded if they fulfill any of the following exclusion criteria:\n\n* prior LTRA use before index date\n* no ICS/LABA FDC Rx within 3 months before index date\n* no prior asthma Dx before index date age on index date less than 18 years\n* on index date less than 365 days prior UTS registration\n* prior COPD Dx before index date (including index date)\n* any prior LAMA use before index date (including index date)"}, {"id": "OG002", "title": "ICS/LABA Fixed Dose Combination (Switchers)", "description": "The first ICS/LABA FDC prescription record during study period with different ICS and/or LABA drug substance component as compared to the preceding FDC prescription qualifies for cohort entry and its event date will be set as index date. Same ICS/LABA FDC, but different device (e.g. switch from DPI to pMDI) will trigger cohort entry to this cohort as well.\n\nPatients will be excluded if they fulfil any of the following exclusion criteria:\n\n* prior use of the same ICS/LABA FDC (evaluated on drug substance and device level) before index date\n* preceding ICS/LABA FDC Rx not within 3 months before index date\n* no prior asthma Dx before index date\n* age on index date less than 18 years\n* on index date less than 365 days prior UTS registration\n* prior COPD Dx before index date (including index date)\n* any prior LAMA use before index date (including index date)"}, {"id": "OG003", "title": "ICS Dose Increase of ICS/LABA Fixed Dose Combination User", "description": "The first ICS/LABA FDC prescription record during study period which represent a dose increase of ICS daily dose as compared to the preceding FDC prescription qualifies for cohort entry and its event date will be set as index date.\n\nPatients will be excluded if they fulfill any of the following exclusion criteria:\n\n* preceding ICS/LABA FDC Rx within 3 months before index date\n* no prior asthma Dx before index date\n* age on index date less than 18 years\n* on index date less than 365 days prior UTS registration\n* prior COPD Dx before index date (incl. index date)\n* any prior LAMA use before index date (incl. index date)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "940"}, {"groupId": "OG001", "value": "3704"}, {"groupId": "OG002", "value": "11135"}, {"groupId": "OG003", "value": "1561"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "comment": "NA = \\<5, for compliance with Independent Scientific Advisory Committee (ISAC) requirements, any covariate resulting in counts less than 5 will be reported as \"\\<5\" without any further reporting."}, {"groupId": "OG001", "value": "9"}, {"groupId": "OG002", "value": "49"}, {"groupId": "OG003", "value": "12"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "In this non-interventional study based on existing data, All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed.", "description": "In this non-interventional study based on existing data, All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed.", "eventGroups": [{"id": "EG000", "title": "Spiriva Respimat", "description": "The first Spiriva Respimat prescription record during study period qualifies for cohort entry and its event date will be set as index date.\n\nPatients will be excluded if they fulfill any of the following exclusion criteria:\n\n* prior Spiriva Respimat use before index date\n* no Inhaled corticosteroids (ICS)/ Long-acting beta agonists (LABA) Fixed Dose Combination (FDC) Prescription Record (Rx) within 3 months before index date\n* no prior asthma Diagnosis Record (Dx) before index date\n* age on index date less than 18 years\n* on index date less than 365 days prior Up-to-standard (UTS) registration\n* prior Chronic Obstructive Pulmonary Disease (COPD) Dx before index date (including index date)\n* any prior Long-acting muscarinic antagonists (LAMA) use (including index date)", "deathsNumAffected": 0, "deathsNumAtRisk": 0, "seriousNumAffected": 0, "seriousNumAtRisk": 0, "otherNumAffected": 0, "otherNumAtRisk": 0}, {"id": "EG001", "title": "Leukotriene Receptor Antagonist (LTRA)", "description": "The first LTRA prescription record during study period qualifies for cohort entry and its event date will be set as index date.\n\nPatients will be excluded if they fulfill any of the following exclusion criteria:\n\n* prior LTRA use before index date\n* no ICS/LABA FDC Rx within 3 months before index date\n* no prior asthma Dx before index date age on index date less than 18 years\n* on index date less than 365 days prior UTS registration\n* prior COPD Dx before index date (including index date)\n* any prior LAMA use before index date (including index date)", "deathsNumAffected": 0, "deathsNumAtRisk": 0, "seriousNumAffected": 0, "seriousNumAtRisk": 0, "otherNumAffected": 0, "otherNumAtRisk": 0}, {"id": "EG002", "title": "ICS/LABA Fixed Dose Combination (Switchers)", "description": "The first ICS/LABA FDC prescription record during study period with different ICS and/or LABA drug substance component as compared to the preceding FDC prescription qualifies for cohort entry and its event date will be set as index date. Same ICS/LABA FDC, but different device (e.g. switch from DPI to pMDI) will trigger cohort entry to this cohort as well.\n\nPatients will be excluded if they fulfil any of the following exclusion criteria:\n\n* prior use of the same ICS/LABA FDC (evaluated on drug substance and device level) before index date\n* preceding ICS/LABA FDC Rx not within 3 months before index date\n* no prior asthma Dx before index date\n* age on index date less than 18 years\n* on index date less than 365 days prior UTS registration\n* prior COPD Dx before index date (including index date)\n* any prior LAMA use before index date (including index date)", "deathsNumAffected": 0, "deathsNumAtRisk": 0, "seriousNumAffected": 0, "seriousNumAtRisk": 0, "otherNumAffected": 0, "otherNumAtRisk": 0}, {"id": "EG003", "title": "ICS Dose Increase of ICS/LABA Fixed Dose Combination User", "description": "The first ICS/LABA FDC prescription record during study period which represent a dose increase of ICS daily dose as compared to the preceding FDC prescription qualifies for cohort entry and its event date will be set as index date.\n\nPatients will be excluded if they fulfill any of the following exclusion criteria:\n\n* preceding ICS/LABA FDC Rx within 3 months before index date\n* no prior asthma Dx before index date\n* age on index date less than 18 years\n* on index date less than 365 days prior UTS registration\n* prior COPD Dx before index date (incl. index date)\n* any prior LAMA use before index date (incl. index date)", "deathsNumAffected": 0, "deathsNumAtRisk": 0, "seriousNumAffected": 0, "seriousNumAtRisk": 0, "otherNumAffected": 0, "otherNumAtRisk": 0}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights."}, "pointOfContact": {"title": "Boehringer Ingelheim, Call Center", "organization": "Boehringer Ingelheim", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2018-08-03", "uploadDate": "2021-05-11T03:38", "filename": "Prot_002.pdf", "size": 649240}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2019-01-17", "uploadDate": "2021-05-11T03:38", "filename": "SAP_003.pdf", "size": 1398509}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T4202", "name": "Oculocerebral Syndrome With Hypopigmentation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069447", "term": "Tiotropium Bromide"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000010276", "term": "Parasympatholytics"}, {"id": "D000018680", "term": "Cholinergic Antagonists"}, {"id": "D000018678", "term": "Cholinergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M416", "name": "Tiotropium Bromide", "asFound": "Liver Cancer", "relevance": "HIGH"}, {"id": "M5241", "name": "Bromides", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M13189", "name": "Parasympatholytics", "relevance": "LOW"}, {"id": "M20760", "name": "Cholinergic Antagonists", "relevance": "LOW"}, {"id": "M20758", "name": "Cholinergic Agents", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AntiConv", "name": "Anticonvulsants"}]}}, "hasResults": true}